NCCN Guidelines Updated
- FLASCO
- August 11, 2016
- News
NCCN has published NEW NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for the following disease type:
- Testicular Cancer, Version 2.2016
NCCN has published updates to the NCCN Guidelines® and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 1.2017.
- Adjuvant Treatment (SCL-5)
- Extensive stage: PCI + thoracic RT changed to PCI ± thoracic RT.
- Principles of Systemic therapy (SCL-C 1 of 3)
- Subsequent systemic therapy
- The decision point of “relapse <2–3 mo, PS 0-2” versus “relapse >2–3 mo up to 6 mo” removed.
- Category 1 recommendation removed from topotecan. This is now a category 2A recommendation.
- Ifosfamide removed as an option.
- Nivolumab ± ipilimumab added as a treatment option with a category 2A recommendation.
- Statement modified: “Consider dose reduction or growth factor support for patients with PS 2”
- Response Assessment added to the Guidelines (SCL-C 2 of 3)
- Limited-stage
- For patients receiving adjuvant therapy, response assessment should occur only after completion of initial therapy; do not repeat scans to assess response during adjuvant treatment.
- For patients receiving systemic therapy + concurrent RT, response assessment should occur only after completion of initial therapy; do not repeat scans to assess response during initial treatment.
- For patients receiving systemic therapy alone or sequential systemic therapy followed by RT, response assessment by CT chest/liver/adrenal with contrast should occur after every 2 cycles of systemic therapy and at completion of therapy.
- Extensive-stage
- During systemic therapy, response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy and at completion of therapy.
- For patients with asymptomatic brain metastases receiving systemic therapy before whole-brain RT, brain MRI (preferred) or CT with contrast should be repeated after every 2 cycles of systemic therapy and at completion of therapy.
- Subsequent systemic therapy
- Response assessment by CT chest/liver/adrenal with contrast should occur after every 2–3 cycles of systemic therapy.
- Limited-stage
- Subsequent systemic therapy
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To access the NCCN Biomarkers Compendium®, please visit NCCN.org/biomarkers.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.
Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.
